Michael C. Donegan - Sep 29, 2021 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
CAO and VP of Finance
Signature
/s/ Michael C. Donegan
Stock symbol
TXMD
Transactions as of
Sep 29, 2021
Transactions value $
$0
Form type
4
Date filed
10/1/2021, 05:00 PM
Previous filing
Jul 2, 2021
Next filing
Dec 2, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Units Award $0 +39K $0.00 39K Sep 29, 2021 Common Stock 39K $0.00 Direct F1, F2
transaction TXMD Non-Qualified Stock Option (right to buy) Other $0 -50K -100% $0.00* 0 Sep 29, 2021 Common Stock 50K $5.01 Direct F3, F4
transaction TXMD Non-Qualified Stock Option (right to buy) Other $0 -100K -100% $0.00* 0 Sep 29, 2021 Common Stock 100K $8.92 Direct F3, F5
transaction TXMD Non-Qualified Stock Option (right to buy) Other $0 -40K -100% $0.00* 0 Sep 29, 2021 Common Stock 40K $6.83 Direct F3, F6
transaction TXMD Non-Qualified Stock Option (right to buy) Other $0 -100K -100% $0.00* 0 Sep 29, 2021 Common Stock 100K $5.16 Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units (RSUs) issued pursuant to the Issuer's stock option exchange program approved by stockholders at the Issuer's 2021 annual meeting (the "Option Exchange Program"). Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.
F3 Stock options exchanged for RSUs pursuant to the Option Exchange Program.
F4 Underlying shares were subject to vesting as follows: 12,500 shares on the first anniversary date of the grant, 12,500 shares on the second anniversary date of the grant, 12,500 shares on the third anniversary date of the grant, and 12,500 shares on the fourth anniversary date of the grant.
F5 Underlying shares were subject to vesting as follows: equal monthly installments over 12 months.
F6 Underlying shares were subject to vesting as follows: 13,333 shares on the first anniversary date of the grant, 13,333 shares on the second anniversary date of the grant, and 13,334 shares on the third anniversary date of the grant.
F7 Underlying shares were subject to vesting as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant.